Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials

American Heart Journal

Volumn 154, Issue 6, 2007, Pages 1085.e1-1085.e6

  De Luca, Giuseppe ^a   Marino, Paolo ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PAMAPARIN; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW;

EID: 36148985732     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.08.029     Document Type: Article

References (25)

1. Van de Werf F., Ardissino D., Betriu A., et al., for the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24 (2003) 28-66
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). Circulation 110 (2004) 588-636
3. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 (1992) 242-250
4. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
5. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
6. Egger M., and Smith G.D. Bias in location and selection of studies. BMJ 316 (1998) 61-66
7. De Luca G., Suryapranata H., Stone G.W., et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 1 (2007) 1 [electronic publication ahead of print]
8. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
9. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
10. Ross A.M., Molhoek P., Lundergan C., et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104 (2001) 648-652
11. Baird S.H., Menown I.B.A., McBride S.J., et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J. 23 (2002) 627-632
12. Antman E.M., Louwerenburg H.W., Baars H.F., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 105 (2002) 1642-1649
13. Wallentin L., Bergstrand L., Dellborg M., et al., for the ASSENT PLUS Investigators. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction: the ASSENT Plus study. Eur Heart J 24 (2003) 897-908
14. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108 (2003) 135-142
15. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
16. Wang X.K., Zhang Y., Yang C.M., et al. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction. Clin Drug Investig 26 (2006) 341-349
17. Rogers W.J., Canto J.G., Lambrew C.T., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 36 (2000) 2056-2063
18. Klein W., Kraxner W., Hodl R., et al., for the GRACE Investigators. Patterns of use of heparins in ACS: correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 90 (2003) 519-527
19. Fareed J., Leong W.L., Hoppensteadt D.A., et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 30 (2004) 703-713
20. Martel N., Lee J., and Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106 (2005) 2710-2715
21. Eikelboom J.W., Quinlan D.J., Mehta S.R., et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112 (2005) 3855-3867
22. Bijsterveld N.R., Peters R.J., Murphy S.A., et al. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 42 (2003) 2083-2089
23. Sinnaeve P.R., Huang Y., Bogaerts K., et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 152 (2006) 684.e1-684.e9
24. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
25. Chen Z.M., Jiang L.X., Chen Y.P., et al., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621